Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triumph-02: Brivestobart (GLS-012) + Zimberelimab (GLS-010) in Advanced NSCLC
NCT05978401Phase 2Not yet recruiting
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of brivestobart in non-small cell lung cancer (NSCLC), sponsored by Guangzhou Gloria Biosciences Co., Ltd.. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
brivestobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05978401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978401.